Afatinib treatment of severe respiratory failure due to malignant lymphangitis in a dialysis patient with squamous cell carcinoma of the lung.
Osamu KanaiMitsuteru KoizumiTakanori ItoTadashi MioPublished in: BMJ case reports (2024)
Patients on dialysis have limited treatment options for advanced lung cancer because some chemotherapeutic agents are unavailable due to renal dysfunction. A man in his 70s on peritoneal dialysis presented with persistent fever refractory to antibiotics for 2 weeks. Subsequent whole-body CT showed a 5 cm diameter mass in the right lower lobe of the lung with right-sided pleural effusion and osteolytic metastasis of the right iliac bone. The patient was diagnosed with squamous cell carcinoma (cT3N2M1b, stage IVB) harbouring the p.Gly719Ala point mutation on exon 18 of the epidermal growth factor receptor. The patient developed severe respiratory failure due to malignant lymphangitis after a bronchoscopy. He received 30 mg/day of afatinib, resulting in tumour shrinkage and recovery from respiratory failure. We advocate for aggressive screening of driver oncogenes in patients with lung cancer on dialysis, including those with squamous cell lung cancer.
Keyphrases
- respiratory failure
- end stage renal disease
- peritoneal dialysis
- chronic kidney disease
- epidermal growth factor receptor
- extracorporeal membrane oxygenation
- squamous cell carcinoma
- mechanical ventilation
- case report
- advanced non small cell lung cancer
- tyrosine kinase
- computed tomography
- squamous cell
- acute respiratory distress syndrome
- image quality
- early onset
- intensive care unit
- magnetic resonance imaging
- positron emission tomography
- magnetic resonance
- ejection fraction
- radiation therapy
- newly diagnosed
- drug induced
- postmenopausal women
- body composition
- bone loss
- gestational age